Roche acquires CAPP Medical

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROCHE acquired CAPP Medical, a genomics research company founded by members of Stanford University, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.

CAPP Medical’s novel technology is designed to isolate and quantify small amounts of ctDNA through a blood draw, which can be used for cancer therapy selection and monitoring tumor response and resistance to therapy.

“Roche believes focused and high quality next generation sequencing assays using simple blood draws have the potential to significantly advance the time of cancer diagnosis and change routine cancer diagnostic monitoring and may be highly cost effective compared to today’s current standard of using PET and CT imaging to monitor tumor progression,” said Roland Diggelmann, COO of Roche Diagnostics.

CAPP Medical is a privately held company founded in October 2013. CAPP Medical’s technology focuses on assay design and the bioinformatics that allow for the detection of multiple mutations with a single assay.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login